Mesoblast Ltd., of Melbourne, Australia, said its Phase II trial for lumbar spinal fusion met its safety and efficacy endpoints, with results suggesting that NeoFuse, its product comprising allogeneic mesenchymal precursor cells (MPCs), is as effective for interbody lumbar fusion as bone autograft without the need for a second surgical procedure and its attendant morbidity risks.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter